Key Developments: Alphatec Holdings Inc (ATEC.O)
1.95USD
24 May 2013
$0.01 (+0.52%)
$1.94
$1.94
$1.95
$1.90
31,104
196,415
$2.40
$1.41
Latest Key Developments (Source: Significant Developments)
The Law Firm of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By The Board Of Directors Of Alphatec Holdings Inc
Levi & Korsinsky, LLP announced that it is investigating Alphatec Holdings Inc and its Board of Directors, in connection with possible claims of breaches of fiduciary duty. Full Article
Alphatec Holdings Inc Reaffirms FY 2013 Guidance
Alphatec Holdings Inc announced that for fiscal 2013, it expects revenue to be in a range between $204 million and $210 million and adjusted EBITDA to be in a range of $24 million to $27 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $207 million for fiscal 2013. Full Article
Alphatec Holdings Inc Receives FDA 510(K) Market Clearance For Its Alphatec Solus Internal Fixation Anterior Lumbar Interbody Fusion Device
Alphatec Holdings Inc announced that the Company has received clearance from the U.S. Food and Drug Administration (FDA) to market and sell patented Alphatec Solus internal fixation anterior lumbar interbody fusion (ALIF) device. The device's 510(K) application was filed with the FDA during the fourth quarter of 2012. The Alphatec Solus ALIF device features two counter-rotating titanium blades, which deploy into adjacent vertebrae on a zero-degree axis, locking the device in place. This provides four points of fixation delivered in what the Company believes is an industry single step. The patented device is designed to provide enhanced segmental stability with a simplified surgical technique, while providing substantial spacing to insert bone graft to help promote rapid fusion at the site. Alphatec Solus is designed to provide fast, easy and effective stabilization for a surgeon's ALIF procedures. Full Article
Alphatec Holdings Inc Issues FY 2013 Guidance In Line With Analysts' Estimates
Alphatec Holdings Inc announced that for fiscal 2013, it expects revenue to be in a range between $204 million and $210 million and adjusted EBITDA guidance to be in the range of $24 million to $27 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $206 million and EBITDA of $26 million for fiscal 2013. Full Article
Alphatec Holdings Inc Receives U.S. FDA 510(K) Market Clearance for Two New Products
Alphatec Holdings Inc announced that it has recently received 510(k) market clearance from the U.S. Food and Drug Administration (FDA) for two new products in the Company's new product pipeline: An anchored, anterior cervical interbody device, called Pegasus, which offers single-step deployment of the anchoring blades without the need for impaction; and, A new MIS system, called ILLICO FS Facet Fixation System, which enables spine surgeons to immobilize and stabilize spinal segments without the need for pedicle screw and rod constructs. Additionally, the Company also announced that it has received Shonin approval in Japan from the Pharmaceuticals and Medical Devices Agency to market and sell three lines of Company's PEEK Spinal Spacers, including the SD, the LCC and the TL, which are used in posterior spine fusion procedures. PEEK, or polyetheretherketone, is a radiolucent material containing radiographic markers, which enhance interbody visualization and alignment during the fusion process. Full Article
Alphatec Holdings Inc Lowers FY 2012 Guidance
Alphatec Holdings Inc announced that for fiscal 2012, it expects revenue to be in a range between $189-$193 million, or minus 4% to minus 2% growth over 2011, adjusted EBITDA guidance to be in the range of $18-$20 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $194 million and EBITDA of $20 million for fiscal 2012. Full Article
Alphatec Holdings Inc's Alphatec Spine Receives Board Approval to Acquire Assets of Spine Implant Business
Alphatec Holdings Inc, the parent company of Alphatec Spine, Inc, announced that its board of directors has approved its plans to acquire certain assets of Phygen, LLC, a spinal implant manufacturer based in Irvine, CA. The purchase price for the assets is approximately $15.2 million in stock and cash. On August 7, 2012, Alphatec Spine first announced that it had signed a letter of intent to acquire the assets of Phygen, LLC. Full Article
Alphatec Holdings, Inc. Lowers FY 2012 Guidance
Alphatec Holdings, Inc. announced that for fiscal 2012, it expects revenue be in the range of $196-$204 million, or minus 1% to plus 3% growth over 2011 and adjusted EBITDA guidance will be in the range of $20-$24 million (or 10% to 12% of sales). According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $204 million and EBITDA of $26 million for fiscal 2012. Full Article
Alphatec Holdings, Inc. Reaffirms FY 2012 Guidance
Alphatec Holdings, Inc. announced that for fiscal 2012, it expects revenue to be in the range of $204 million to $209 million and adjusted EBITDA guidance to be in the range of $23 million to $27 million (or 11% to 13% of sales). According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $207 million and EBITDA of $23 million for fiscal 2012. Full Article
Alphatec Holdings, Inc. Issues FY 2012 Guidance
Alphatec Holdings, Inc. announced that for fiscal 2012, it expects revenue to a range of $204 million to $209 million and expects annual adjusted EBITDA to be in the range of $23 million to $27 million. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
